Sodium-Glucose Cotransporter 2 Inhibitors and Serious Liver Events in Patients With Cirrhosis
In this cohort study of adults with cirrhosis who were receiving diuretic therapy, the findings suggest that SGLT-2 inhibitor use was associated with a lower incidence of serious liver events. These findings further suggest a potential role for SGLT-2 inhibitors in cirrhosis management.
Authors
- Omar T. Sims (ORCID: https://orcid.org/0000-0002-3207-2231)
- Rashid Abdel-Razeq (ORCID: https://orcid.org/0000-0001-8928-3294)
- Mohamad-Noor Abu-Hammour (ORCID: https://orcid.org/0000-0001-5579-9807)
- Dian Chiang
- Aravinthan Vignarajah (ORCID: https://orcid.org/0000-0002-3758-0024)
- Nishanthi Vigneswaramoorthy
- Raneem Khedraki
Institutions
- Cleveland Clinic (US)
- SUNY Upstate Medical University (US)
- Cleveland Clinic Lerner College of Medicine (US)
- University School (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.18470
- Citations
- 6
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 8.13